RoboSense Wins CES 2020 Innovation Award for Autonomous Vehicle Technology
8.11.2019 12:19:00 EET | Business Wire | Press release
RoboSense http://www.robosense.ai, the world’s leading autonomous driving LiDAR perception solution provider, announced today that it has won the CES 2020 Innovation Award the second year in a row for autonomous vehicle technology. RoboSense won this year’s CES 2020 Innovation Award for the first MEMS-based Smart LiDAR Sensor, the RoboSense RS-LiDAR-M1, winning in the Vehicle Intelligence and Self-Driving Technology category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191108005194/en/
RoboSense RS-LiDAR-M1 (Graphic: Business Wire)
The RoboSense award-winning RS-LiDAR-M1 is the world’s first and only MEMS-based smart LiDAR sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC(System on a Chip). The RS-LiDAR-M1 goes beyond traditional LiDAR, providing full data collection and comprehension. As a ground-breaking product, the RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but also processes road data in real-time, with a built-in AI algorithm and SoC, while at the same time synchronizing high-precision positioning output; road traffic signage; lane markings, driving areas, road curbs, and obstacle detection; tracking; and classification. Also, it is the world’s smallest MEMS-based solid-state LiDAR, providing a low cost, high stability, and superior manufacturability to meet automotive-grade and serial production requirements.
“Driving Safety is the most critical challenge for the Autonomous driving vehicles. Perception is the first sense for the AD vehicles to precept the surrounding environment. To ensure a completely safe perception working in all conditions, LiDAR with smart perception algorithm and supporting functions are indispensable. We are very proud that our smart LiDR sensor concept have been recognized by the customers and different application users, ” said Dr. Leilei Shinohara, RoboSense Vice President of R&D.
The RoboSenseRS-LiDAR-M1 Smart LiDAR Sensor will be on display in the Innovation Awards Showcaseat the upcoming CES 2020. The complete list of CES 2020 Innovation Honorees, including product descriptions and photos, can be found at CES.tech/Innovation. RoboSense will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About CES & CES Innovation Awards
An annual program that celebrates outstanding design, the CES Innovation Awards recognizes the best technology products of the year. The CES Innovation Awards are sponsored by the Consumer Technology Association (CTA)™, owner and producer of CES, the world’s largest and most influential technology event.
CES 2020 will showcase life-changing technology across every major industry. CES provides access to the very latest transformative tech, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports tech, machine learning and more. For the latest news and show announcements, visit CES.tech. Follow CES online at CES.tech and on social.
About RoboSense
Founded in 2014, RoboSense is the world’s leading provider of LiDAR environment perception solutions designed to provide a higher performance, safer, more reliable, and lower cost LiDAR system for autonomous vehicles. RoboSense has entered into strategic partnerships with many top car companies, tier one manufacturers and technology companies with a global reach. For more information about RoboSense, visit: https://www.robosense.ai
Photos:
CES 2020 Innovation Award Honoree Logo: http://www.thomas-pr.com/136/photos/robosenseces2020innovationawardlogo.html
RS-LiDAR-M1 Smart LiDAR Sensor: http://www.thomas-pr.com/136/photos/robosensem1lidar.html
RoboSense Logo: http://www.thomas-pr.com/136/photos/robosenselogo.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005194/en/
Contact information
Press:
Karen Thomas/Eva Yutani
Emails: kthomas@thomaspr.com / eyutani@thomaspr.com
(631) 549-7575 website: http://www.thomaspr.com
Company:
Cassie Gong, Overseas PR Manager
Email: sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom